This information is intended for use by health professionals

1. Name of the medicinal product

Atropine Sulfate 3mg in 10ml Solution for injection in pre-filled syringe

2. Qualitative and quantitative composition

Each 1ml of solution contains 0.3 mg of Atropine Sulfate.

Each pre-filled syringe (10 ml) contains 3 mg Atropine Sulfate.

For the full list of excipients, see section 6.1.


3. Pharmaceutical form

Solution for injection in pre-filled syringe.

Clear and practically particulate free solution, pH 3 - 4.5.

4. Clinical particulars
4.1 Therapeutic indications

Cardiopulmonary resuscitation - in the treatment of asystole

As an antidote to cholinesterase inhibitors

As an antidote to organophosphate pesticides and in mushroom poisoning.

In Arrhythmias - Bradycardia associated with acute myocardial infarction.

4.2 Posology and method of administration

Cardiopulmonary Resuscitation:

Adults and children over 12 years

The usual dose to treat asystole is 3mg in 10ml by intravenous injection, once only. If venous access is unavailable a single 3mg in 10ml dose of atropine may be administered via an endotracheal tube. This should be followed by ventilation to aid drug absorption. If necessary this may be repeated to a total maximum dose of 6mg.

As an Antidote to Cholinesterase Inhibitors:

Adults and Children over 12 years

2mg by intravenous or intramuscular injection. Repeat dose every 5-10 minutes until signs of atropinisation appear.

As an Antidote to Organophosphate Pesticides and in Mushroom Poisoning:

Adults and children over 12 years

2mg by intravenous or intramuscular injection. Repeat dose every 10-30 minutes until muscarinic signs and symptoms subside.

In Arrhythmias:

Adults and children over 12 years

The treatment of bradycardia associated with myocardial infarction 300mcg increasing to 1mg if necessary.

Paediatric population

Not recommended for children under 12 years..

Elderly As for adults, but use with caution.

Method of administration:

Atropine 3mg in 10ml is administered intravenously IV, intramuscular IM and exceptionally endotracheal ET.

4.3 Contraindications

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1

o Closed-angle glaucoma

o Risk of urinary retention because of prostatic or urethral disease

o Myasthenia gravis unless given in conjunction with anticholinesterase

o Breast-feeding (see section 4.6).

o Paralytic Ileus or Pyloric Stenosis

o Severe Ulcerative Colitis

4.4 Special warnings and precautions for use

Use with caution in case of:

Prostatic enlargement

Renal or hepatic insufficiency

Cardiac insufficiency, arrhythmias, hyperthyroidism

Chronic obstructive pulmonary disease, as a reduction in bronchial secretions may lead to the formation of bronchial plugs.

Reflux oesophagitis

Fever, or when ambient temperature is high

In the elderly, who are more susceptible to adverse effects.

4.5 Interaction with other medicinal products and other forms of interaction

Combinations to be taken into account

Other medicinal products with anticholinergic activity such as tricyclic antidepressants, some H1-anithistamines, antiparkinsonian medicines (MAOI's), disopyramide, mequitazine, phenothiazine, neuroleptic medicines, antispasmodics and quinidine, because of the increased risk of atropinic adverse effects (urinary retention, constipation, dry mouth).

4.6 Fertility, pregnancy and lactation


Studies in animal have shown a teratogenic effect of atropine in one specie with very high doses.

Data on a limited number of exposed pregnancies indicate no adverse effects of atropine on pregnancy or on the health of the foetus/new-born child.

To date, no other epidemiological data are available.

Atropine should not be used during pregnancy unless clearly necessary.


Atropine is excreted in breast milk, and may cause neurological toxicity in the infant. Moreover atropine inhibits lactation.

Breast-feeding is thus contraindicated if atropine should be used.

4.7 Effects on ability to drive and use machines

Atropine may cause drowsiness or blurred vision and patients should be advised of it.

4.8 Undesirable effects

The most commonly reported adverse events are due to the action of atropine on muscarinic and, at high doses, on nicotinic receptors. These effects are dose-related and usually reversible when therapy is discontinued.

Immune system disorders:


Psychiatric disorders:

Nervousness, confusional state, especially in the elder1y. At higher doses hallucinations, restlessness, and delirium.

Eye disorders:

Dilatation of the pupils with loss of accommodation and photophobia, decrease in lachrymal secretion, increase in intraocular pressure.

Cardiac disorders:

Transient bradycardia followed by tachycardia, palpitations, arrhythmias.



Respiratory, thoracic and mediastinal disorders:

Thickening of bronchial secretions.

Gastrointestinal disorders:

Dry mouth, nausea, vomiting, and constipation.

Renal and urinary disorders:

Urinary retention.

Skin and subcutaneous tissue:

Dry skin



Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at:

4.9 Overdose


Flushing and dryness of the skin, dilated pupils, dry mouth and tongue, tachycardia, rapid respiration, hyperpyrexia, hypertension, nausea, vomiting. Symptoms of CNS stimulation include restlessness, confusion, hallucinations, paranoid and psychotic reactions, incoordination, delirium and occasionally convulsions. In severe overdose, CNS depression may occur with coma, circulatory and respiratory failure and death.


Treatment of overdosage with Atropine Sulfate Solution for injection consists of symptomatic and supportive therapy. General measures include: reduction of body temperature, administration of fluids orally or intravenously, monitoring of ECG or excitement with diazepam, urinary catheterisation to avoid urinary retention. The use of physostigmine as an antidote to atropine is controversial.

5. Pharmacological properties
5.1 Pharmacodynamic properties

Pharmacotherapeutic group: anticholinergic agents.

ATC code: A03BA01.

Atropine is an antimuscarinic agent which competitively antagonises acetylcholine at postganglionic nerve endings, thus affecting receptors in the exocrine glands, smooth muscle, cardiac muscle and the central nervous system.

Peripheral effects include decreased production of saliva, sweat, nasal, lachrymal and gastric secretions, decreased intestinal motility and inhibition of micturition.

Atropine increases sinus rate and sinoatrial and AV conduction. Usually heart rate is increased, but there may be an initial bradycardia.

Atropine inhibits secretions throughout the respiratory tract and relaxes bronchial smooth muscle producing bronchodilation.

5.2 Pharmacokinetic properties

Following intravenous administration, the peak increase in heart rate occurs within 2-4 minutes.

Atropine is distributed widely throughout the body and crosses the blood brain barrier. The elimination half-life is about 2 to 5 hours. Up to 50% of the dose is protein bound.

Atropine is incompletely metabolised in the liver and is excreted in the urine as unchanged drug and metabolites. About 50% of the dose is excreted within 4 hours and 90% in 24 hours.

5.3 Preclinical safety data

There are no preclinical data of relevance to the prescriber which are additional to that already included in other sections of the SmPC

6. Pharmaceutical particulars
6.1 List of excipients

Water for Injections,

Sulfuric Acid (for pH adjustments),


6.2 Incompatibilities

Atropine Sulfate injection is reported to be physically incompatible with bromides, iodides, alkalis, noradrenaline bitartrate, metaraminol bitartrate and sodium bicarbonate. A haze or precipitate may form within 15 minutes when Atropine Sulfate is mixed with methohexital sodium solutions.

6.3 Shelf life

18 Months

6.4 Special precautions for storage

Store below 25°C. Protect from light

6.5 Nature and contents of container

Sterile aqueous solution for injection in Glass (Type I) 10ml prefilled syringes.

6.6 Special precautions for disposal and other handling

Use once and discard any remaining solution.

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

7. Marketing authorisation holder

Aurum Pharmaceuticals Ltd

T/A Martindale Pharma

Bampton Road

Harold Hill




United Kingdom

8. Marketing authorisation number(s)

PL 12064/0057

9. Date of first authorisation/renewal of the authorisation

Date of first authorisation: 22 December 1997

10. Date of revision of the text